Oncogenic transcription factors like c-MYC and RAS can upregulate glutamine transporters and enzymes, such as alanine-serine cysteine transporter 2 (ASCT2) and glutaminase (GLS)-1, in cancer cells, increasing their metabolic activity. This evidence concerns the gene GLS and cancer.